Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia

Trial Profile

Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Torticollis
  • Focus Therapeutic Use
  • Sponsors Revance Therapeutics
  • Most Recent Events

    • 03 Nov 2017 According to a Revance Therapeutics media release, company scheduled meeting for the fourth quarter of 2017 with the U.S. Food & Drug Administration to review the data from the Phase 2 trial and to determine next steps for the program.
    • 08 Jun 2017 Preliminary 24-week results (Data cut off: 8 Dec, 2016) presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 05 Jun 2017 New 24 week results from this study published in a Revance Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top